Latest Vita Life Sciences (ASX:VLS) News

Vita Life Sciences forecasts solid sales and profit growth for FY2025, driven by strong performances in Malaysia and Singapore, while cautiously managing challenges in China exports.

Vita Life Sciences delivered a robust first half in 2025 with record revenue and profit growth, driven by strong performances in Australia and Southeast Asia. The company also raised its interim dividend and expanded marketing efforts.

Vita Life Sciences reported a robust half-year performance with revenue up 15.4% to A$45.5 million and a 12.2% rise in net profit, driven by strong growth in Australia and Southeast Asia. The company also increased its interim dividend to 4.5 cents per share, signaling confidence despite challenges in China.

Vita Life Sciences projects solid revenue growth of up to 16% for the first half of 2025, driven by strong performance in Australia, Malaysia, and Singapore, even as sales in China dip below last year’s levels.